Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains-Reference-Cited by-同舟云学术

Antimicrobial Activity and Spectrum of PPI-0903M (T-91825), a Novel Cephalosporin, Tested against a Worldwide Collection of Clinical Strains

Published:2005-08 Issue:8 Volume:49 Page:3501-3512
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sader Helio S.¹²,Fritsche Thomas R.¹,Kaniga Koné³,Ge Yigong³,Jones Ronald N.¹⁴

Affiliation:

1. JMI Laboratories, North Liberty, Iowa

2. Universidade Federal de São Paulo, São Paulo, Brazil

3. Peninsula Pharmaceuticals, Alameda, California

4. Tufts University School of Medicine, Boston, Massachusetts

Abstract

ABSTRACT PPI-0903M is a novel N -phosphono-type cephalosporin active against oxacillin-resistant staphylococci and many other gram-positive organisms. This study evaluated the in vitro activity and spectrum of PPI-0903M against 1,478 recent clinical isolates collected from 80 medical centers (22 countries). PPI-0903M demonstrated broader in vitro activity against gram-positive bacteria, particularly against multidrug-resistant staphylococci and streptococci of current clinical concern, than currently available extended-spectrum cephalosporins while maintaining similar activity against gram-negative pathogens.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.49.8.3501-3512.2005

Reference17 articles.

1. Genome and virulence determinants of high virulence community-acquired MRSA

2. In Vitro Activities of RWJ-54428 (MC-02,479) against Multiresistant Gram-Positive Bacteria

3. Clinical and Laboratory Standards Institute. 2005. Performance standards for antimicrobial susceptibility testing 15th informational supplement M100-S15. Clinical and Laboratory Standards Institute Wayne Pa.

4. Frank, A. L., J. F. Marcinak, P.D. Mangat, and P. C. Schreckenberger. 1999. Increase in community-acquired methicillin-resistant Staphylococcus aureus in children. Clin. Infect. Dis.29:935-936.

5. In Vitro Activity of S-3578, a New Broad-Spectrum Cephalosporin Active against Methicillin-Resistant Staphylococci

Cited by 133 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cephalosporin resistance, tolerance, and approaches to improve their activities;The Journal of Antibiotics;2023-12-19

2. Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents;Expert Review of Anti-infective Therapy;2023-11-02

3. Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus;Microbiology Spectrum;2023-02-14

4. The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition;Frontiers in Microbiology;2022-03-24

5. In vitro activity of ceftaroline and other antimicrobial agents against Gram positive bacterial isolates: Descriptive study from a university hospital;Indian Journal of Medical Microbiology;2021-09